Celling Technologies Signs Exclusive Agreement to Research and Develop Adipose Tissue Stem Cell Technology in Regenerative Medicine Institutes
AUSTIN, Texas, Nov. 9 Celling Technologies, a subsidiary of SpineSmith Partners, is collaborating with Tissue Genesis, Inc. to research potential applications for adipose tissue derived adult stem cells. SpineSmith acquired the global rights in spine for Tissue Genesis' adipose (fat) tissue derived stem cell technology in November of 2007. Replacing the prior arrangement, this new exclusive agreement allows Celling Technologies to further research adipose tissue derived stem cells in a variety of human applications, including orthopedics, vascular, trauma, plastics and disease, in certain agreed upon medical institutes.
Celling's team of scientists will collaborate with Tissue Genesis, and its licensees, to research adipose tissue derived stem cell applications at certain medical institutions throughout the world. "We believe adult stem cells will revolutionize modern medicine, and our business development efforts are positioning the company to continue leading the research and development of cellular therapy. The agreement with Tissue Genesis solidifies our position as a leader, and continues to build the opportunity for surgeons and institutions interested in the future of regenerative medicine," says Kevin Were, Director of Business Development for Celling Technologies.
This agreement allows Celling Technologies to offer Tissue Genesis' technology into its expanding network of surgeons and facilities around the world. The Regenerative Institute platform allows for collaboration between scientists, engineers and surgeons to drive research validating the efficacy of these adult stem cell therapies. "We believe our agreement with Celling Technologies gives Tissue Genesis a unique relationship to expand research with our Cell Isolation System technology, and collaborating with scientists and physicians," says Anton Krucky, CEO of Tissue Genesis.
The Tissue Genesis Cell Isolation System rapidly processes (in about an hour) autologous (patient-derived) adipose tissue and concentrates large quantities of regenerative cells (including adult stem cells) at point of care. This technology matches well with the current SpineSmith product portfolio of surgical implants and the current cell therapy products being investigated by Celling Technologies.
About SpineSmith Partners, LP
SpineSmith Partners, LP is dedicated to creating better ways to facilitate and accelerate the healing of spinal disorders through integration of innovative medical devices and biologic technologies. SpineSmith designs, develops, and markets implants and biologics for surgical fixation, correction, and tissue regeneration of the spine. SpineSmith's dedication to a collaborative approach between scientists, engineers and spine surgeons results in the development of truly innovative biological and hardware technologies.
About Celling Technologies
Celling Technologies, a SpineSmith Partners company, works closely with surgeons, scientists and engineers to research and develop innovative technologies in the emerging field of regenerative medicine. Celling's product offering focuses on autologous adult stem cell therapy and the devices and services that complement these procedures
About Tissue Genesis, Inc.
An emerging leader in adipose-derived cell therapy and regenerative medicine, Tissue Genesis, Inc. is a high-growth, clinical-stage company based in Honolulu, Hawai'i. Industry-leading engineers and scientists have developed a proprietary process for Tissue Genesis that may deliver innovative medical solutions for a wide range of existing medical problems, including: cardiac and peripheral vascular disease; orthopedic injuries; cosmetic and soft tissue defects; and many other applications. For more information, visit www.tissuegenesis.com.
SOURCE Celling Technologies
You May Also Like